Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$463.15 USD

463.15
947,949

+1.39 (0.30%)

Updated Sep 26, 2024 04:00 PM ET

Pre-Market: $465.00 +1.85 (0.40%) 8:12 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biogen's (BIIB) Lecanemab Shows Benefit but With Side Effects

by Zacks Equity Research

Detailed data from Biogen (BIIB) and Eisai's Clarity AD shows that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of cognitive decline but is associated with adverse events like brain hemorrhage.

AstraZeneca (AZN) Boosts Cell Therapies With Neogene Deal

by Zacks Equity Research

The acquisition of Neogene is set to give AstraZeneca (AZN) access to the latter's next-generation T-cell receptor therapies.

Sarepta's (SRPT) DMD Gene Therapy BLA Gets FDA Priority Review

by Zacks Equity Research

The FDA accepts Sarepta's (SRPT) regulatory filing seeking accelerated approval for SRP-9001, a gene therapy for DMD indication. A final decision is expected by May 2023.

BioMarin (BMRN) Up After FDA Scraps AdCom Meet for BLA Filing

by Zacks Equity Research

The FDA decides not to hold an advisory committee meeting for BioMarin Pharmaceuticals' (BMRN) regulatory filing seeking approval for hemophilia A gene therapy, valrox.

AbbVie's (ABBV) Skyrizi Gets EU Nod for Crohn's Disease

by Zacks Equity Research

AbbVie's (ABBV) Skyrizi becomes the first specific IL-23 inhibitor to get approval for Crohn's disease in the European Union.

Merck (MRK) Keytruda Advanced Gastric Cancer Study Meets Goal

by Zacks Equity Research

Top-line data from a late-stage study shows that Merck's (MRK) Keytruda combined with chemotherapy improved overall survival in patients with advanced gastric cancer.

GSK to Withdraw Blenrep From U.S. Market on FDA Request

by Zacks Equity Research

GSK, at the request of the FDA, is set to withdraw the U.S. marketing authorization for Blenrep. The FDA's request comes after the failure of a phase III confirmatory study, DREAMM-3.

Should iShares MSCI USA Min Vol Factor ETF (USMV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for USMV

Imago (IMGO) Shares Surge 104% on Buyout Offer From Merck

by Zacks Equity Research

Imago BioSciences (IMGO) to be acquired by pharma-giant Merck (MRK) for $1.35 billion. The transaction is likely to close by first-quarter 2023.

Should You Invest in the VanEck Biotech ETF (BBH)?

by Zacks Equity Research

Sector ETF report for BBH

AbbVie (ABBV) BLA for Epcoritamab Gets FDA Priority Tag

by Zacks Equity Research

The FDA grants priority review status to AbbVie's (ABBV) BLA for epcoritamab for the relapsed/refractory large B-cell lymphoma (LBCL), a form of NHL.

Why Vertex Pharmaceuticals (VRTX) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Sanofi's (SNY) Rare Anemia Drug Enjaymo Gets EU Approval

by Zacks Equity Research

Sanofi's (SNY) Enjaymo gets approval to treat hemolytic anemia in adult patients with cold agglutinin disease (CAD) in Europe.

VRTX or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

VRTX vs. TECH: Which Stock Is the Better Value Option?

Merck (MRK) Outpaces Industry YTD: What's in Store for 2023?

by Zacks Equity Research

Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments keep Merck's (MRK) stock afloat in 2023.

Eli Lilly (LLY) Stock Up 26.7% YTD: What's in Store for 2023?

by Zacks Equity Research

Lilly (LLY) expects to launch five new medicines by 2023-end, including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.

Moderna's (MRNA) Omicron BA.4/5 Booster Jab Study Meets Goal

by Zacks Equity Research

Moderna's (MRNA) Omicron-targeting bivalent COVID vaccines exhibit substantial antibody response compared with an original booster dose of Spikevax.

AstraZeneca's (AZN) 3 Cancer Drugs Get CHMP Nod for Expanded Use

by Zacks Equity Research

The CHMP recommends expanded use of AstraZeneca's (AZN) three key cancer drugs, Lynparza, Enhertu and Imfinzi.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

AstraZeneca's (AZN) Imfinzi/Imjudo Combo Gets Another FDA Nod

by Zacks Equity Research

AstraZeneca (AZN) gets its second FDA approval for the Imfinzi+Imjudo combo in non-small cell lung cancer (NSCLC) indication.

Sanofi (SNY), Regeneron Dupixent Gets CHMP Nod for Skin Disease

by Zacks Equity Research

The CHMP recommends approval of Sanofi's (SNY) Dupixent for the treatment of prurigo nodularis, a chronic inflammatory skin disease.

Jazz's (JAZZ) Q3 Earnings Beat Estimates, New Drugs Drive Sales

by Zacks Equity Research

Jazz's Q3 earnings and sales beat expectations on strong demand for new drugs and drugs added with the GW Pharmaceuticals acquisition. The company raises the mid-point of its 2022 sales guidance.

AstraZeneca's (AZN) Q3 Earnings Beat, EPS Growth View Up

by Zacks Equity Research

AstraZeneca (AZN) beats third-quarter estimates for earnings while sales come in line. AZN raises its 2022 earnings growth guidance, keeping its sales forecast unchanged.

Reata (RETA) Q3 Earnings Beat, Stock Up on Pipeline Updates

by Zacks Equity Research

Reata (RETA) reports a narrower-than-expected loss in the third quarter. Stock rises after RETA states that the FDA did not request additional data on the NDA for omaveloxolone in Friedreich's ataxia.

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB